Cowden syndrome laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(12 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{VKG}}
{{CMG}}; {{AE}} {{VKG}}
==Overview==
==Overview==
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
[[Laboratory]] findings consistent with the [[diagnosis]] of [[cowden syndrome]] include [[skin biopsy]], chemistry panels, [[urinalysis]], [[thyroid function tests]] and cbc count.
 
OR
 
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
 
OR
 
[Test] is usually normal for patients with [disease name].
 
OR
 
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
 
OR
 
There are no diagnostic laboratory findings associated with [disease name].


==Laboratory Findings==
==Laboratory Findings==


There are no diagnostic laboratory findings associated with [disease name].
[[Laboratory]] findings consistent with the [[diagnosis]] of [[cowden syndrome]] include:<ref name="pmid25184920">{{cite journal |vauthors=Sano DT, Yang JJ, Tebcherani AJ, Bazzo LA |title=A rare clinical presentation of Desmoplastic Trichilemmoma mimicking Invasive Carcinoma |journal=An Bras Dermatol |volume=89 |issue=5 |pages=796–8 |date=2014 |pmid=25184920 |pmc=4155959 |doi= |url=}}</ref><ref name="pmid24151559">{{cite journal |vauthors=Chippagiri P, Banavar Ravi S, Patwa N |title=Multiple hamartoma syndrome with characteristic oral and cutaneous manifestations |journal=Case Rep Dent |volume=2013 |issue= |pages=315109 |date=2013 |pmid=24151559 |pmc=3787619 |doi=10.1155/2013/315109 |url=}}</ref>
 
*[[Complete blood count|CBC count:]]
OR
**Sign of [[anemia]] may be helpful in screening for [[malignancy]].
 
**Increase in [[WBC]] count may rise the suspicion for [[Lymphoproliferative disorders|lymphoproliferative disorder]].
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
*[[Thyroid function tests]]:
 
**May be helpful in diagnosis of [[hashimoto thyroiditis]], [[adenomas]], and [[carcinomas]].
OR
*[[Urinalysis]]:
 
**May be helpful in [[diagnosis]] of [[kidney]] or [[bladder]] [[malignancy]] when detected [[proteinuria]] or [[hematuria]].
[Test] is usually normal among patients with [disease name].
*[[Calcium]] level
 
**[[Calcium]] level helps in [[diagnosis]] of [[parathyroid]] diseases.
OR
 
Laboratory findings consistent with the diagnosis of [disease name] include:
*[Abnormal test 1]
*[Abnormal test 2]
*[Abnormal test 3]


OR
* [[Liver function tests]]([[Liver function tests|LFT's]]):
** May be helpful in [[diagnosis]] of [[hepatocellular carcinoma]].


Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
*[[Skin biopsy]]:
**May be helpful in [[diagnosis]] of [[Trichilemmoma|trichilemmomas]] and [[Sclerotic fibroma|sclerotic fibromas]].<ref name="pmid22486434">{{cite journal |vauthors=Al-Zaid T, Ditelberg JS, Prieto VG, Lev D, Luthra R, Davies MA, Diwan AH, Wang WL, Lazar AJ |title=Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors |journal=J. Cutan. Pathol. |volume=39 |issue=5 |pages=493–9 |date=May 2012 |pmid=22486434 |doi=10.1111/j.1600-0560.2012.01888.x |url=}}</ref>


=== Gene testing ===
*''[[PTEN (gene)|PTEN]]'' [[Mutations|mutation]] testing by following:<ref name="pmid216593472">{{cite journal |vauthors=Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW |title=Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features |journal=J. Med. Genet. |volume=48 |issue=8 |pages=505–12 |date=August 2011 |pmid=21659347 |doi=10.1136/jmg.2011.088807 |url=}}</ref><ref name="pmid24136893">{{cite journal |vauthors=Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E |title=Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria |journal=J. Natl. Cancer Inst. |volume=105 |issue=21 |pages=1607–16 |date=November 2013 |pmid=24136893 |doi=10.1093/jnci/djt277 |url=}}</ref><ref name="pmid24037976">{{cite journal |vauthors=Mester JL, Moore RA, Eng C |title=PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing? |journal=Oncologist |volume=18 |issue=10 |pages=1083–90 |date=2013 |pmid=24037976 |pmc=3805149 |doi=10.1634/theoncologist.2013-0174 |url=}}</ref>
**Sequence analysis of [[coding region]]
**Deletion/duplication analysis
**Sequence analysis of [[promoter region]]
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 20:57, 7 March 2019

Cowden syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cowden Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cowden syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cowden syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cowden syndrome laboratory findings

CDC on Cowden syndrome laboratory findings

Cowden syndrome laboratory findings in the news

Blogs on Cowden syndrome laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Cowden syndrome laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

Laboratory findings consistent with the diagnosis of cowden syndrome include skin biopsy, chemistry panels, urinalysis, thyroid function tests and cbc count.

Laboratory Findings

Laboratory findings consistent with the diagnosis of cowden syndrome include:[1][2]

Gene testing

References

  1. Sano DT, Yang JJ, Tebcherani AJ, Bazzo LA (2014). "A rare clinical presentation of Desmoplastic Trichilemmoma mimicking Invasive Carcinoma". An Bras Dermatol. 89 (5): 796–8. PMC 4155959. PMID 25184920.
  2. Chippagiri P, Banavar Ravi S, Patwa N (2013). "Multiple hamartoma syndrome with characteristic oral and cutaneous manifestations". Case Rep Dent. 2013: 315109. doi:10.1155/2013/315109. PMC 3787619. PMID 24151559.
  3. Al-Zaid T, Ditelberg JS, Prieto VG, Lev D, Luthra R, Davies MA, Diwan AH, Wang WL, Lazar AJ (May 2012). "Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors". J. Cutan. Pathol. 39 (5): 493–9. doi:10.1111/j.1600-0560.2012.01888.x. PMID 22486434.
  4. Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW (August 2011). "Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features". J. Med. Genet. 48 (8): 505–12. doi:10.1136/jmg.2011.088807. PMID 21659347.
  5. Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E (November 2013). "Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria". J. Natl. Cancer Inst. 105 (21): 1607–16. doi:10.1093/jnci/djt277. PMID 24136893.
  6. Mester JL, Moore RA, Eng C (2013). "PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?". Oncologist. 18 (10): 1083–90. doi:10.1634/theoncologist.2013-0174. PMC 3805149. PMID 24037976.

Template:WH Template:WS